New study examines how diabetes and weight-loss drugs affect employment and working hours
Diabetes and weight-loss medications may have economic effects beyond health care spending, according to new research from NYU Abu Dhabi. Using population-wide data from Denmark, the study found that diabetes treatment caused an increased likelihood of employment, while weight-management treatment caused longer working hours among people already employed. The findings also point to implications…
New research published by NYU Abu Dhabi reveals potential economic impacts of diabetes and weight loss medications beyond health care spending. Utilizing Danish population data from 2018 to 2024, the study found diabetes treatment increased employment likelihood and extended working hours among the employed, while weight-loss treatment had less impact on employment but extended work hours for those already employed.
The findings suggest several key takeaways: examining medication effects beyond direct medical costs is crucial; GLP-1 receptor agonists like semaglutide (Ozempic) and Wegovy (Wegovy) show varied effects on labor market outcomes; changes in employment and working hours could offset public spending by generating additional income tax revenue; and further analysis is needed to understand the broader implications for public health and fiscal policy.
Written by urgent.news from Phys.org's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
